Clinical trial NCT06955169: Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
Official title: MOMENTUM-1: A Multicenter, Randomized, Open-Label, Phase II Study of [177LU]LU-DOTATATE in Adults With Progressive Intracranial Grade 1-3 Meningioma
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Intracranial Meningioma
Keywords: MOMENTUM-1
Meningioma
Advanced Intracranial Meningioma
SSTR2
Radiopharmaceuticals
Theranostics
Radioligand Therapy
Lu-DOTATATE
Lutathera
Lead sponsor: RTOG Foundation, Inc.
Sponsor class: OTHER
Collaborators: name: Novartis Pharmaceuticals
First posted: 2025-05-02
Enrollment: 153
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of \[177Lu\]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.

Detailed description: Study participants will be randomized by a 2:1 ratio to receive either \[177Lu\]Lu-DOTATATE or standard of care therapy as deemed appropriate by the local investigator. At time of progression, participants on the standard of care arm may cross-over to the \[177Lu\]Lu-DOTATATE alternative treatment arm.

Eligibility criteria: Inclusion Criteria:

STEP 1 REGISTRATION

* Aged \>= 18 years
* Histologically confirmed diagnosis of WHO grade 1-3 meningioma
* Presence of measurable contrast-enhancing disease on gadolinium-enhanced MRI brain scan defined as at least one lesion with two perpendicular diameters measuring ≥10 mm on two or more axial slices (≤ 5 mm interslice thickness, ≤ 1 mm interslice gap) per current RANO meningioma criteria
* Progression of disease determined by local radiology review per current RANO meningioma criteria, defined as

  * ≥ 15% increase in sum of product of perpendicular measurements of up to 3 measurable target lesions within the last 6 months, or
  * ≥ 25% increase in sum of product of perpendicular measurements of up to 3 measurable target lesions within the last 12 months, or
  * Development of a new measurable lesion
* The following scans must be available for submission for central radiology review:

  * Pre-progression gadolinium-enhanced MRI brain scan
  * Progression gadolinium-enhanced MRI brain scan

STEP 2 REGISTRATION

* Progression of disease determined by central radiology review per current RANO meningioma criteria, defined as

  * ≥ 15% increase in sum of product of perpendicular measurements of up to 3 measurable target lesions within the last 6 months, or
  * ≥ 25% increase in sum of product of perpendicular measurements of up to 3 measurable target lesions within the last 12 months, or
  * Development of a new measurable lesion.
* \[68Ga\]Ga-DOTATATE uptake on PET-CT. Positive uptake is defined as a Krenning score \>= 3, based on the uptake in at least one target lesion, referenced to the uptake in the liver and spleen.
* If randomized to the control (standard of care) arm, both the patient and investigator must agree NOT to receive SSTR2-targeted therapy, surgical resection, or radiation therapy.
* Patients must be willing and able to undergo regular MRI scans of the brain and \[68Ga\]Ga-DOTATATE PET-CT imaging during the study.
* Patients must have recovered to CTCAE grade ≤1 or pretreatment baseline from clinically significant adverse events related to prior therapy (exclusions include alopecia, lymphopenia, sensory neuropathy ≤ grade 2, or other ≤ grade 2 not constituting a safety risk based on the investigator's judgment).
* Adequate organ and bone marrow function as defined below (within 28 days prior to step 2 registration):

  * Absolute neutrophil count (ANC) ≥ 1500/mm3
  * Platelet count ≥ 75,000/mm3
  * Hemoglobin ≥ 8 g/dL
  * Creatinine clearance (calculated by the Cockroft-Gault method) ≥40mL/min
  * Total serum bilirubin ≤ 3 x ULN (except participants with Gilbert's Syndrome, who can have a total bilirubin ≤ 5 x ULN)
  * Potassium within normal limits.

Exclusion Criteria:

* Patients with a clinical diagnosis of NF2-related schwannomatosis or with a known molecular diagnosis of NF2-related schwannomatosis.
* Patients with radiation-associated meningiomas.
* Patients with known intraspinal meningiomas or meningioma metastases outside the skull/spinal column.
* Prior SSTR2-targeted therapy, e.g. Somatostatin LAR or short-acting Octreotide.
* Unstable neurological symptoms requiring steroids to control symptoms at a dose of \>2 mg of dexamethasone (or equivalent) daily within 28 days prior to step 2 registration.
* Patients requiring immediate local therapy (e.g. surgical resection).
* Surgical procedure within the timeframes listed below, prior to step 2 registration.

  * 28 days from any prior craniotomy
  * 7 days from stereotactic biopsy Note: There is no limit to the number of prior surgical interventions
* Treatment within the timeframes specified below, prior to step 2 registration.

  * 28 days (or 5 half-lives, whichever is longer) for cytotoxic chemotherapy, biologic agent, investigational agent or any other systemic agent prescribed for the purpose of treating meningioma
  * 6 weeks from nitrosoureas Note: There is no limit to the number of prior systemically administered therapeutic agents.
* Prior external beam radiation, interstitial brachytherapy or stereotactic radiosurgery cumulative radiation dose of \> 70 Gy or the last dose of radiotherapy \< 24 weeks (6 months) prior to step 2 registration
* Peptide receptor radionuclide therapy at any time prior to registration.
* Known hypersensitivity to somatostatin analogues or any component of the \[68Ga\]Ga- DOTATATE or \[177Lu\]Lu-DOTATATE formulations.
* Active infection requiring current use of intravenous therapy with antibiotics.
* Active cardiovascular disease: cerebral vascular accident/stroke (≤ 6 months prior to registration), myocardial infarction (≤ 6 months prior to registration), congestive heart failure (≥ NYHA class II), unstable angina pectoris, or serious cardiac arrhythmia requiring medication.
* An active malignancy ≤ 3 years. Note: Patients with a malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
* Pregnant and/or breastfeeding patients who are unwilling to discontinue breast feeding.
* Participants of childbearing potential must have a negative pregnancy test within 14 days of study entry.

Primary outcomes:
measure: Progression Free Survival (PFS)
timeFrame: Assessed up to 4 years
Secondary outcomes:
measure: Progression free survival at 6 months (PFS-6)
timeFrame: 6 months
measure: Overall Survival at 12 months (OS-12)
timeFrame: 12 months
measure: Overall survival (OS)
timeFrame: Assessed up to 4 years
measure: Progression-free Survival after cross-over (PFS2)
timeFrame: Assessed up to 4 years
measure: Disease Control Rate (DCR)
timeFrame: Assessed up to 4 years
measure: Objective response rate (ORR)
timeFrame: Assessed up to 4 years
measure: Number of participants by highest grade treatment-emergent adverse event (TEAE):
timeFrame: Assessed up to 4 years
measure: Number of participants who discontinue treatment due to TEAE
timeFrame: Assessed up to 4 years
Other outcomes:
Locations:
Study officials:
affiliation: NYU Langone Health
name: Erik P Sulman, MD,PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Yale University
name: Sylvia C Kurz, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: